What is Dynavax Technologies?
Founded in 1996 and headquartered in Emeryville, California, Dynavax Technologies Corporation operates as a clinical-stage immunotherapy firm. The company specializes in harnessing the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its research and development pipeline is robust, targeting multiple cancer indications, the prevention of hepatitis B, and disease-modifying therapies for asthma. By focusing on the intersection of immunology and vaccine technology, Dynavax maintains a unique market position that bridges the gap between traditional pharmaceutical interventions and next-generation biological therapies.
How much funding has Dynavax Technologies raised?
Dynavax Technologies has raised a total of $293.9M across 5 funding rounds:
Stock Offering
$45M
Stock Offering
$20.1M
Stock Offering
$43.9M
Stock Offering
$85.9M
Debt
$99M
Stock Issuance/Offering (2004): $45M, investors not publicly disclosed
Stock Issuance/Offering (2010): $20.1M, investors not publicly disclosed
Stock Issuance/Offering (2010): $43.9M, investors not publicly disclosed
Stock Issuance/Offering (2013): $85.9M, investors not publicly disclosed
Debt (2021): $99M backed by Coalition for Epidemic Preparedness Innovations
Key Investors in Dynavax Technologies
Coalition for Epidemic Preparedness Innovations
An innovative global partnership between public, private, philanthropic, and civil society organizations that develops vaccines to stop future epidemics.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
Undisclosed Institutional Investor
Undisclosed investor participating in the funding round.
What's next for Dynavax Technologies?
With the recent infusion of capital, Dynavax is well-positioned to accelerate its clinical trial milestones and expand its manufacturing capabilities. The strategic focus will likely remain on the commercialization of its vaccine portfolio and the advancement of its oncology pipeline. As the company moves forward, the primary objective will be to translate its TLR stimulation research into scalable, market-ready products that address significant unmet medical needs. Investors will be closely monitoring the firm's ability to maintain its current momentum while navigating the complex regulatory landscape inherent to the biotech sector.
See full Dynavax Technologies company page
